Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: chalu2 who wrote (509)	9/16/1999 11:30:00 PM
From: James Perry	Respond to of 1025

On the other hand, you also could anticipate the price would increase more than $50 per share over the present value. True, some part of the settlement should be built into the present price. But considering the fact that Igen would have then turned substantially profitable, and that the settlement would strongly affirm the soundness of the process, the market value, and the strength of ownership by Igen, I should think all that would really give legs to the prospects of further gains from market penetration. At that point, if I assumed that Igen would make no further strides forward beyond those in present view (food & drug, high thruput and point of care), I still would want to hold my shares for at least $200. But of course, there will be further strides, if only in the form of important new tests - for instance, cancer.